Pfizer (PFE) said Saturday that its Phase 3 BREAKWATER study showed a 61% objective response rate for the BRAFTOVI combination therapy in patients with BRAF V600E-mutant metastatic colorectal cancer, compared to 40% for standard chemotherapy, based on an independent review.
The BRAFTOVI treatment, which includes cetuximab and mFOLFOX6, has been approved by the FDA for newly diagnosed patients with this mutation, the company stated.
Patients treated with the BRAFTOVI combination had a median response duration of 13.9 months, compared to 11.1 months for those receiving normal chemotherapy, while early overall survival data showed favorable results for the new treatment, Pfizer added.
Pfizer said the safety profile of the BRAFTOVI combination was in line with the known effects of the individual treatments.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。